Decision: Favourable

Study Title:

An open-label, randomized, Phase 3 clinical trial of IO102- IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma

  • NREC Code:


  • Decision:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof. Paul Donnellan

  • PI Institution:

    University Hospital Galway

  • Sponsor:

    IO Biotech ApS

Scroll to Top